Lotric-Furlan Stanka, Maraspin-Carman Vera, Cimperman Joze, Ogrinc Katarina, Stopar Tanja, Strle Franc
Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia.
Wien Klin Wochenschr. 2002 Jul 31;114(13-14):530-2.
Serum and cerebrospinal fluid (CSF) procalcitonin levels were assessed and compared for different groups of patients with Lyme borreliosis.
50 adult patients with Lyme borreliosis, referred to our department from March to June 2001, were included in this prospective study. Patients were divided into three groups. The first group consisted of 20 consecutive patients with typical solitary erythema migrans, representing early localised Lyme borreliosis, the second group comprised 20 patients with early disseminated Lyme borreliosis (10 with multiple erythema migrans and 10 with neuroborreliosis), and 10 patients with acrodermatitis chronica athrophicans represented the group with chronic Lyme borreliosis. Blood specimens were taken from all patients included in the study, but CSF samples were restricted to those with disseminated and chronic Lyme borreliosis. The serum and CSF procalcitonin levels were determined utilizing the LUMI PCT (an immunoluminometric assay using two antigen-specific monoclonal antibodies).
Serum and CSF procalcitonin levels were in normal range in the large majority of patients. The levels of serum procalcitonin did not differ in the three groups of patients with Lyme borreliosis (p = 0.5006). The corresponding values for patients with solitary erythema migrans (early localised Lyme borreliosis), early disseminated Lyme borreliosis, and chronic Lyme borreliosis were 0.26 (0.11-0.43), 0.22 (0.10-0.67), and 0.28 (0.13-0.66) microgram/ml, respectively. Moreover, procalcitonin levels in CSF were also low and comparable for patients with multiple erythema migrans (median 0.38, range 0.24-0.54 microgram/ml), neuroborreliosis (median 0.16, range 0.10-0.47 microgram/ml), and acrodermatitis chronica athrophicans (median 0.30, range 0.15-0.45 microgram/ml). The differences were not statistically significant (p = 0.7579).
In the large majority of patients with Lyme borreliosis procalcitonin values are within normal range. Serum and CSF procalcitonin levels are of no value for differentiation between early localised, early disseminated and chronic Lyme borreliosis.
对不同组莱姆病患者的血清和脑脊液降钙素原水平进行评估和比较。
本前瞻性研究纳入了2001年3月至6月转诊至我科的50例成年莱姆病患者。患者分为三组。第一组由20例连续的典型单发游走性红斑患者组成,代表早期局限性莱姆病;第二组包括20例早期播散性莱姆病患者(10例有多发性游走性红斑,10例有神经莱姆病),10例慢性萎缩性肢端皮炎患者代表慢性莱姆病组。采集了研究中所有患者的血液标本,但脑脊液样本仅限于播散性和慢性莱姆病患者。采用LUMI PCT(一种使用两种抗原特异性单克隆抗体的免疫发光测定法)测定血清和脑脊液降钙素原水平。
大多数患者的血清和脑脊液降钙素原水平在正常范围内。三组莱姆病患者的血清降钙素原水平无差异(p = 0.5006)。单发游走性红斑(早期局限性莱姆病)、早期播散性莱姆病和慢性莱姆病患者的相应值分别为0.26(0.11 - 0.43)、0.22(0.10 - 0.67)和0.28(0.13 - 0.66)微克/毫升。此外,多发性游走性红斑患者(中位数0.38,范围0.24 - 0.54微克/毫升)、神经莱姆病患者(中位数0.16,范围0.10 - 0.47微克/毫升)和慢性萎缩性肢端皮炎患者(中位数0.30,范围0.15 - 0.45微克/毫升)的脑脊液降钙素原水平也较低且相当。差异无统计学意义(p = 0.7579)。
大多数莱姆病患者的降钙素原值在正常范围内。血清和脑脊液降钙素原水平对区分早期局限性、早期播散性和慢性莱姆病无价值。